In-silico Drug Discovery Market Size to Hit USD 10.73 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on In-silico Drug Discovery Market

5.1. COVID-19 Landscape: In-silico Drug Discovery Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global In-silico Drug Discovery Market, By Product Type

8.1. In-silico Drug Discovery Market Revenue and Volume Forecast, by Product Type

8.1.1. Software as a Service

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Consultancy as a Service

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Software

8.1.3.1. Market Revenue and Volume Forecast

Chapter 9. Global In-silico Drug Discovery Market, By Application

9.1. In-silico Drug Discovery Market Revenue and Volume Forecast, by Application

9.1.1. Target Identification

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Lead Optimization

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Preclinical Testing

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Clinical Trials

9.1.4.1. Market Revenue and Volume Forecast

9.1.5. Adverse Effect Prediction

9.1.5.1. Market Revenue and Volume Forecast

Chapter 10. Global In-silico Drug Discovery Market, By End-User

10.1. In-silico Drug Discovery Market Revenue and Volume Forecast, by End-User

10.1.1. Pharmaceutical and Biopharmaceutical Companies

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Contract Research Organizations (CROs)

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Academic and Research Institutes

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Others

10.1.4.1. Market Revenue and Volume Forecast

Chapter 11. Global In-silico Drug Discovery Market, By Target Therapeutic Area

11.1. In-silico Drug Discovery Market Revenue and Volume Forecast, by Target Therapeutic Area

11.1.1. Oncological Disorders

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Metabolic Disorders

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. HIV

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Infectious Diseases

11.1.4.1. Market Revenue and Volume Forecast

11.1.5. Musculoskeletal Disorders

11.1.5.1. Market Revenue and Volume Forecast

11.1.6. Mental Disorders

11.1.6.1. Market Revenue and Volume Forecast

11.1.7. Neurological Disorders

11.1.7.1. Market Revenue and Volume Forecast

11.1.8. Others

11.1.8.1. Market Revenue and Volume Forecast

Chapter 12. Global In-silico Drug Discovery Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Product Type

12.1.2. Market Revenue and Volume Forecast, by Application

12.1.3. Market Revenue and Volume Forecast, by End-User

12.1.4. Market Revenue and Volume Forecast, by Target Therapeutic Area

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Product Type

12.1.5.2. Market Revenue and Volume Forecast, by Application

12.1.5.3. Market Revenue and Volume Forecast, by End-User

12.1.5.4. Market Revenue and Volume Forecast, by Target Therapeutic Area

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Product Type

12.1.6.2. Market Revenue and Volume Forecast, by Application

12.1.6.3. Market Revenue and Volume Forecast, by End-User

12.1.6.4. Market Revenue and Volume Forecast, by Target Therapeutic Area

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Product Type

12.2.2. Market Revenue and Volume Forecast, by Application

12.2.3. Market Revenue and Volume Forecast, by End-User

12.2.4. Market Revenue and Volume Forecast, by Target Therapeutic Area

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Product Type

12.2.5.2. Market Revenue and Volume Forecast, by Application

12.2.5.3. Market Revenue and Volume Forecast, by End-User

12.2.5.4. Market Revenue and Volume Forecast, by Target Therapeutic Area

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Product Type

12.2.6.2. Market Revenue and Volume Forecast, by Application

12.2.6.3. Market Revenue and Volume Forecast, by End-User

12.2.6.4. Market Revenue and Volume Forecast, by Target Therapeutic Area

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Product Type

12.2.7.2. Market Revenue and Volume Forecast, by Application

12.2.7.3. Market Revenue and Volume Forecast, by End-User

12.2.7.4. Market Revenue and Volume Forecast, by Target Therapeutic Area

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Product Type

12.2.8.2. Market Revenue and Volume Forecast, by Application

12.2.8.3. Market Revenue and Volume Forecast, by End-User

12.2.8.4. Market Revenue and Volume Forecast, by Target Therapeutic Area

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Product Type

12.3.2. Market Revenue and Volume Forecast, by Application

12.3.3. Market Revenue and Volume Forecast, by End-User

12.3.4. Market Revenue and Volume Forecast, by Target Therapeutic Area

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Product Type

12.3.5.2. Market Revenue and Volume Forecast, by Application

12.3.5.3. Market Revenue and Volume Forecast, by End-User

12.3.5.4. Market Revenue and Volume Forecast, by Target Therapeutic Area

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Product Type

12.3.6.2. Market Revenue and Volume Forecast, by Application

12.3.6.3. Market Revenue and Volume Forecast, by End-User

12.3.6.4. Market Revenue and Volume Forecast, by Target Therapeutic Area

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Product Type

12.3.7.2. Market Revenue and Volume Forecast, by Application

12.3.7.3. Market Revenue and Volume Forecast, by End-User

12.3.7.4. Market Revenue and Volume Forecast, by Target Therapeutic Area

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Product Type

12.3.8.2. Market Revenue and Volume Forecast, by Application

12.3.8.3. Market Revenue and Volume Forecast, by End-User

12.3.8.4. Market Revenue and Volume Forecast, by Target Therapeutic Area

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Product Type

12.4.2. Market Revenue and Volume Forecast, by Application

12.4.3. Market Revenue and Volume Forecast, by End-User

12.4.4. Market Revenue and Volume Forecast, by Target Therapeutic Area

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Product Type

12.4.5.2. Market Revenue and Volume Forecast, by Application

12.4.5.3. Market Revenue and Volume Forecast, by End-User

12.4.5.4. Market Revenue and Volume Forecast, by Target Therapeutic Area

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Product Type

12.4.6.2. Market Revenue and Volume Forecast, by Application

12.4.6.3. Market Revenue and Volume Forecast, by End-User

12.4.6.4. Market Revenue and Volume Forecast, by Target Therapeutic Area

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Product Type

12.4.7.2. Market Revenue and Volume Forecast, by Application

12.4.7.3. Market Revenue and Volume Forecast, by End-User

12.4.7.4. Market Revenue and Volume Forecast, by Target Therapeutic Area

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Product Type

12.4.8.2. Market Revenue and Volume Forecast, by Application

12.4.8.3. Market Revenue and Volume Forecast, by End-User

12.4.8.4. Market Revenue and Volume Forecast, by Target Therapeutic Area

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Product Type

12.5.2. Market Revenue and Volume Forecast, by Application

12.5.3. Market Revenue and Volume Forecast, by End-User

12.5.4. Market Revenue and Volume Forecast, by Target Therapeutic Area

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Product Type

12.5.5.2. Market Revenue and Volume Forecast, by Application

12.5.5.3. Market Revenue and Volume Forecast, by End-User

12.5.5.4. Market Revenue and Volume Forecast, by Target Therapeutic Area

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Product Type

12.5.6.2. Market Revenue and Volume Forecast, by Application

12.5.6.3. Market Revenue and Volume Forecast, by End-User

12.5.6.4. Market Revenue and Volume Forecast, by Target Therapeutic Area

Chapter 13. Company Profiles

13.1. Schrödinger, Inc

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Insilico Medicine:

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Atomwise, Inc

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Exscientia

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Iktos:

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Deep Genomics

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Insitro:

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Recursion Pharmaceuticals

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Valo Health

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. BenevolentAI

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

Thein-silico drug discovery market size is expected to increase from USD 4.17 billion in 2025 to USD 10.73 billion by 2034.

The in-silico drug discovery market is expected to grow at a compound annual growth rate (CAGR) of around 11.09% from 2025 to 2034.

The major players in the in-silico drug discovery market include Schrödinger, Inc., Atomwise, Inc, Recursion Pharmaceuticals, GenScript, Valo Health, Insitro, BenevolentAI, Atomwise, Inc, and Insilico Medicine

The driving factors of the in-silico drug discovery market are the rapid technology advancement in computational biology and the increasing development of new pharmacological compounds are anticipated to boost the expansion of the in-silico drug discovery market

North America region will lead the global in-silico drug discovery market during the forecast period 2025 to 2034.